ModernMedicine Resource Center More Topics

Hepatology Resource Center

Real-world DAA therapy shows gains in community settingPhysicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Study: DAA all-oral combination successful in treating hepatitis CEarly data shows promise in “real-world” effectiveness.
DAAs do not increase risk of hepatic decompensation in HCV patientsResearchers say theirs is first national study with a large population to examine possible link.
DAA therapy effective in advanced liver disease in real-world studyAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
Researchers unveil optimal timing of HCV therapy in transplantationA new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant.
Oral DAA combination found effective in HCV patientsDirect-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author.
DAAs aid treatment of hepatitis C patients with cancerDirect-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.
DAA treatment restricted for Canadian hepatitis C patientsPatients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.
Liver distress: Top 10 care and cost concernsThis slide show highlights the top 10 issues we covered this year on managing treatment of patients with HCV infection.
HCV patients on DAAs need hepatitis B testingA test for hepatitis B virus should be done for patients beginning treatment with direct-acting antiviral therapy for their hepatitis C, experts advise.